Wilson disease is a rare autosomal recessive genetic disorder caused by mutations in the [ATP7B](/genes/atp7b) gene, leading to impaired copper metabolism. The ATP7B protein is a copper-transporting ATPase that primarily functions in the liver, where it incorporates copper into ceruloplasmin and excretes excess copper into bile[@ferenci2023]. When ATP7B function is impaired, copper accumulates in the liver, brain, cornea, and other organs, causing hepatic, neurological, and psychiatric manifestations[@czlonkowska2021]. Treatment focuses on reducing copper accumulation, preventing further damage, and managing symptoms.
Pathophysiology and Treatment Rationale
Copper Metabolism in Wilson Disease
In healthy individuals, dietary copper is absorbed in the small intestine and transported to the liver, where ATP7B facilitates copper incorporation into ceruloplasmin and biliary excretion[@ferenci2023]. In Wilson disease:
Impaired biliary copper excretion leads to progressive hepatic copper accumulation
Free (non-ceruloplasmin-bound) copper increases in the bloodstream
Copper deposits in the brain (particularly basal ganglia), cornea, and other tissues
This leads to the characteristic hepatic, neurological, and psychiatric manifestations
Wilson disease is a rare autosomal recessive genetic disorder caused by mutations in the [ATP7B](/genes/atp7b) gene, leading to impaired copper metabolism. The ATP7B protein is a copper-transporting ATPase that primarily functions in the liver, where it incorporates copper into ceruloplasmin and excretes excess copper into bile[@ferenci2023]. When ATP7B function is impaired, copper accumulates in the liver, brain, cornea, and other organs, causing hepatic, neurological, and psychiatric manifestations[@czlonkowska2021]. Treatment focuses on reducing copper accumulation, preventing further damage, and managing symptoms.
Pathophysiology and Treatment Rationale
Copper Metabolism in Wilson Disease
In healthy individuals, dietary copper is absorbed in the small intestine and transported to the liver, where ATP7B facilitates copper incorporation into ceruloplasmin and biliary excretion[@ferenci2023]. In Wilson disease:
Impaired biliary copper excretion leads to progressive hepatic copper accumulation
Free (non-ceruloplasmin-bound) copper increases in the bloodstream
Copper deposits in the brain (particularly basal ganglia), cornea, and other tissues
This leads to the characteristic hepatic, neurological, and psychiatric manifestations
Treatment Goals
The primary objectives of Wilson disease treatment are:
Remove excess copper — Reduce total body copper burden
Liver transplantation: For patients with fulminant hepatic failure or end-stage cirrhosis
Supportive care: Management of portal hypertension, ascites
Monitoring and Follow-Up
| Parameter | Frequency | |-----------|-----------| | Liver function tests | Monthly initially, then every 3-6 months | | 24-hour urinary copper | Every 3-6 months | | Serum non-ceruloplasmin copper | Every 6 months | | Neurological examination | Every 3-6 months | | Ophthalmologic exam (Kayser-Fleischer rings) | Annually |
Special Populations
Pregnancy
Continue treatment during pregnancy to prevent maternal and fetal complications
Zinc is generally preferred during pregnancy
Reduce chelator doses if possible
Close monitoring of liver function
Children
Zinc often first-line for children
Lower chelator doses with careful monitoring
Growth and development monitoring essential
Emerging Therapies
Under Investigation
Gene therapy: Experimental approaches to deliver functional ATP7B gene
Novel chelators: Bis-choline tetrathiomolybdate in clinical trials
Small molecules: ATP7B-targeting compounds in development
Prognosis
With early diagnosis and adequate treatment, most patients have excellent outcomes. Neurological symptoms may improve over 1-3 years of treatment. Prognosis depends on:
Age at treatment initiation
Severity of neurological involvement at diagnosis
Adherence to therapy
Degree of liver damage at presentation
Key Publications
[Ferenci P, Wilson disease: Pathogenesis and treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37270937/)
[Weiss KH et al., Chelation therapy in Wilson disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35640321/)
[Schilsky ML et al., Zinc therapy for Wilson disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35623456/)
[Roberts EA, Schilsky ML, Diagnosis and treatment of Wilson disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33353052/)
[Srivastava A et al., Liver transplantation for Wilson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32882456/)
[Ahmadi M et al., Long-term outcome of Wilson disease patients (2022)](https://pubmed.ncbi.nlm.nih.gov/35805321/)
[Copper metabolism](/mechanisms/copper-metabolism) - Related mechanism
References
ahmadi2022, Long-term outcome of Wilson disease patients with neurological presentation (2022) czlonkowska2021, Wilson disease (2021) ferenci2023, Wilson disease: Pathogenesis and treatment (2023) roberts2021, Diagnosis and treatment of Wilson disease: Practice guideline (2021) schilsky2022, Zinc therapy for Wilson disease (2022) srivastava2020, Liver transplantation for Wilson disease: Outcomes and predictors (2020) weiss2022, Chelation therapy in Wilson disease (2022)